Volume | 919,728 |
|
|||||
News | (1) | ||||||
Day High | 5.6463 | Low High |
|||||
Day Low | 5.00 |
Company Name | Stock Ticker Symbol | Market | Type |
---|---|---|---|
Capricor Therapeutics Inc | CAPR | NASDAQ | Common Stock |
Open Price | Low Price | High Price | Close Price | Prev Close |
---|---|---|---|---|
5.26 | 5.00 | 5.6463 | 5.04 | 4.82 |
Trades | Volume | VWAP | Dollar Volume | Avg Volume | 52 Week Range |
---|---|---|---|---|---|
6,435 | 919,728 | $ 5.21 | $ 4,790,586 | - | 2.68 - 8.2212 |
Last Trade Time | Type | Quantity | Stock Price | Currency |
---|---|---|---|---|
18:33:39 | 50 | $ 5.13 | USD |
Capricor Therapeutics Inc Financials
Market Cap | Shares in Issue | Float | Revenue | Profit/Loss | EPS | PE Ratio |
---|---|---|---|---|---|---|
157.63M | 31.40M | - | 25.18M | -22.29M | -0.71 | - |
Short Interest | Dividends Per Share | Dividend Yield | Ex-Div Date | Insider B/S | Insider % Owned |
---|---|---|---|---|---|
- | - | - | - |
Capricor Therapeutics News
Loading Messages....
{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}} |
Loading Messages....
Historical CAPR Price Data
Period | Open | High | Low | VWAP | Avg. Daily Vol | Change | % |
---|---|---|---|---|---|---|---|
1 Week | 5.98 | 6.05 | 4.685 | 5.08 | 521,670 | -0.74 | -12.37% |
1 Month | 6.29 | 7.28 | 4.685 | 5.92 | 330,107 | -1.05 | -16.69% |
3 Months | 4.05 | 7.28 | 3.56 | 5.61 | 305,831 | 1.19 | 29.38% |
6 Months | 2.74 | 7.28 | 2.68 | 4.81 | 269,530 | 2.50 | 91.24% |
1 Year | 4.13 | 8.2212 | 2.68 | 4.73 | 212,827 | 1.11 | 26.88% |
3 Years | 3.92 | 8.2212 | 2.56 | 4.56 | 265,459 | 1.32 | 33.67% |
5 Years | 0.50 | 12.32 | 0.2526 | 5.92 | 756,259 | 4.74 | 948.00% |
Capricor Therapeutics Description
Capricor Therapeutics, Inc. is a San Diego based biotechnology company focused on the development of transformative cell and exosome-based therapeutics for the treatment and prevention of muscular and other select diseases. Capricor's lead candidate, CAP-1002, is an allogeneic cardiac-derived cell therapy that is currently in late-stage clinical development for treating Duchenne muscular dystrophy (DMD). Capricor is also developing its exosome technology as a next-generation therapeutic platform. Capricor's proprietary StealthX¿ exosome platform has potential for a broad range of new therapeutic applications in the field of vaccinology as well as targeted oligonucleotide, protein and small molecule therapeutics to treat or prevent a variety of diseases. |